Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

Articles published in
Acta Neurol Scand
    August 2021
  1. MARIC G, Pekmezovic T, Tamas O, Veselinovic N, et al
    Impact of comorbidities on the disability progression in multiple sclerosis.
    Acta Neurol Scand. 2021 Aug 20. doi: 10.1111/ane.13516.
    >> Share

  2. TELJAS C, Bostrom I, Marrie RA, Landtblom AM, et al
    Validating the diagnosis of multiple sclerosis using Swedish administrative data in Varmland County.
    Acta Neurol Scand. 2021 Aug 6. doi: 10.1111/ane.13514.
    >> Share

    July 2021
  3. JOHANSSON K, Wasling P, Axelsson M
    Fatigue, insomnia and daytime sleepiness in multiple sclerosis versus narcolepsy.
    Acta Neurol Scand. 2021 Jul 19. doi: 10.1111/ane.13497.
    >> Share

    June 2021
  4. ZHUKOVSKY C, Herman S, Wiberg A, Cunningham JL, et al
    Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-beta treatment.
    Acta Neurol Scand. 2021;143:602-607.
    >> Share

    May 2021
  5. LANDTBLOM AM, Berntsson SG, Bostrom I, Iacobaeus E, et al
    Multiple sclerosis and COVID-19: The Swedish experience.
    Acta Neurol Scand. 2021 May 24. doi: 10.1111/ane.13453.
    >> Share

  6. TARAKCI E, Tarakci D, Hajebrahimi F, Budak M, et al
    Supervised exercises versus telerehabilitation. Benefits for persons with multiple sclerosis.
    Acta Neurol Scand. 2021 May 7. doi: 10.1111/ane.13448.
    >> Share

    April 2021
  7. FEASEL CD, Sandroff BM, Motl RW
    Aerobic reserve capacity in multiple sclerosis-Preliminary evidence.
    Acta Neurol Scand. 2021 Apr 29. doi: 10.1111/ane.13441.
    >> Share

    March 2021
  8. KAVALIUNAS A, Danylaite Karrenbauer V, Hillert J
    Socioeconomic consequences of multiple sclerosis-A systematic literature review.
    Acta Neurol Scand. 2021 Mar 22. doi: 10.1111/ane.13411.
    >> Share

    February 2021
  9. OLSSON A, Gustavsen S, Gisselo Lauridsen K, Chenoufi Hasselbalch I, et al
    Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review.
    Acta Neurol Scand. 2021 Feb 16. doi: 10.1111/ane.13401.
    >> Share

    December 2020
  10. TEKEOGLU A, Yeldan I, Ozdincler AR, Saip S, et al
    The efficiency of mirror therapy on drop foot in Multiple Sclerosis Patients.
    Acta Neurol Scand. 2020 Dec 3. doi: 10.1111/ane.13385.
    >> Share

    November 2020
  11. BORGSTROM M, Tisell A, Link H, Wilhelm E, et al
    Retinal thinning and brain atrophy in early MS and CIS.
    Acta Neurol Scand. 2020;142:418-427.
    >> Share

    September 2020
  12. CHESHMAVAR M, Mirmosayyeb O, Badihian N, Badihian S, et al
    Rituximab and glatiramer-acetate in secondary-progressive multiple sclerosis: A randomized-clinical trial.
    Acta Neurol Scand. 2020 Sep 8. doi: 10.1111/ane.13344.
    >> Share

    August 2020
  13. JONS D, Zetterberg H, Malmestrom C, Bergstrom T, et al
    Intrathecal immunoreactivity in people with or without previous infectious mononucleosis.
    Acta Neurol Scand. 2020;142:161-168.
    >> Share

    July 2020
  14. WANDELL P, Fredrikson S, Carlsson AC, Li X, et al
    Multiple sclerosis among first- and second-generation immigrant groups in Sweden.
    Acta Neurol Scand. 2020 Jul 10. doi: 10.1111/ane.13314.
    >> Share

  15. VECCHIO D, Varrasi C, Virgilio E, Spagarino A, et al
    Cannabinoids in multiple sclerosis: A neurophysiological analysis.
    Acta Neurol Scand. 2020 Jul 6. doi: 10.1111/ane.13313.
    >> Share

    June 2020
  16. LAHDENPERA S, Soilu-Hanninen M, Kuusisto HM, Atula S, et al
    Medication adherence/persistence among patients with active multiple sclerosis in Finland.
    Acta Neurol Scand. 2020 Jun 19. doi: 10.1111/ane.13301.
    >> Share

  17. PIRTTISALO AL, Soilu-Hanninen M, Sumelahti ML, Krokki O, et al
    Changes in multiple sclerosis epidemiology in Finland over five decades.
    Acta Neurol Scand. 2020 Jun 4. doi: 10.1111/ane.13295.
    >> Share

    May 2020
  18. MAMOEI S, Hvid LG, Boye Jensen H, Zijdewind I, et al
    Neurophysiological impairments in multiple sclerosis - central and peripheral motor pathways.
    Acta Neurol Scand. 2020 May 31. doi: 10.1111/ane.13289.
    >> Share

  19. ZANONI M, Orlandi E, Rossetti G, Turatti M, et al
    Up-regulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients.
    Acta Neurol Scand. 2020 May 20. doi: 10.1111/ane.13288.
    >> Share

  20. COSTA ARPIN E, Naveiro Soneira J, Lema Bouzas M, Quintela AG, et al
    Epidemiology of multiple sclerosis IN Santiago de Compostela (Spain).
    Acta Neurol Scand. 2020 May 11. doi: 10.1111/ane.13265.
    >> Share

    March 2020
  21. REYES S, Suarez S, Allen-Philbey K, Thomson A, et al
    The impact of social capital on patients with multiple sclerosis.
    Acta Neurol Scand. 2020 Mar 18. doi: 10.1111/ane.13244.
    >> Share

  22. LAAKSO SM, Hekali O, Kurdo G, Martola J, et al
    Trigeminal neuralgia in multiple sclerosis: prevalence and association with demyelination.
    Acta Neurol Scand. 2020 Mar 18. doi: 10.1111/ane.13243.
    >> Share

  23. WILSKI M, Kocur P, Brola W, Tasiemski T, et al
    Psychological factors associated with self-management in multiple sclerosis.
    Acta Neurol Scand. 2020 Mar 2. doi: 10.1111/ane.13236.
    >> Share

  24. ZARGHAMI A, Nourmohammadi ST, Hojjati SMM
    Urbanization theory and socioeconomic changeover of multiple sclerosis in Iran.
    Acta Neurol Scand. 2020;141:256.
    >> Share

    February 2020
  25. RASMAN A
    Air pollution, a risk factor for multiple sclerosis?
    Acta Neurol Scand. 2020 Feb 25. doi: 10.1111/ane.13235.
    >> Share

    January 2020
  26. HELLGREN J, Risedal A, Kallen K
    Rituximab in multiple sclerosis at general hospital level.
    Acta Neurol Scand. 2020 Jan 28. doi: 10.1111/ane.13225.
    >> Share

  27. TURK BORU U, Boluk C, Tasdemir M, Gezer T, et al
    Air pollution, a possible risk factor for multiple sclerosis.
    Acta Neurol Scand. 2020 Jan 18. doi: 10.1111/ane.13223.
    >> Share

    December 2019
  28. MURTONEN A, Sumelahti ML
    Multiple sclerosis prevalence in 2000 and 2010 in Western Finland.
    Acta Neurol Scand. 2019 Dec 14. doi: 10.1111/ane.13203.
    >> Share

    November 2019
  29. WALLIS O, Bol Y, Kohler S, van Heugten C, et al
    Anxiety in multiple sclerosis is related to depressive symptoms and cognitive complaints.
    Acta Neurol Scand. 2019 Nov 6. doi: 10.1111/ane.13191.
    >> Share

  30. SCOTT TF, Diehl D, Elmalik W, Gettings EJ, et al
    Multiple sclerosis relapses contribute to long-term disability.
    Acta Neurol Scand. 2019;140:336-341.
    >> Share

    October 2019
  31. SMOLDERS J, Mimpen M, Oechtering J, Damoiseaux J, et al
    Vitamin D3 supplementation and neurofilament light chain in multiple sclerosis.
    Acta Neurol Scand. 2019 Oct 28. doi: 10.1111/ane.13185.
    >> Share

  32. ZETTERBERG H
    Plasma neurofilament light in progressive multiple sclerosis.
    Acta Neurol Scand. 2019 Oct 16. doi: 10.1111/ane.13184.
    >> Share

  33. CASTREN E, Heinonen T, Makinen K, Hamalainen P, et al
    The rate of neuropsychological assessments in multiple sclerosis has increased - A retrospective study in a Finnish central hospital.
    Acta Neurol Scand. 2019 Oct 4. doi: 10.1111/ane.13175.
    >> Share

    July 2019
  34. FERRARO D, Guicciardi C, De Biasi S, Pinti M, et al
    Plasma Neurofilaments correlate with Disability in Progressive Multiple Sclerosis patients.
    Acta Neurol Scand. 2019 Jul 27. doi: 10.1111/ane.13152.
    >> Share

  35. TOLF A, Fagius J, Carlson K, Akerfeldt T, et al
    Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation.
    Acta Neurol Scand. 2019 Jul 12. doi: 10.1111/ane.13147.
    >> Share

  36. PAKDEL M, Hedstrom A, Bidkhori M, Hadei M, et al
    Do socio-economic factors affect prevalence of multiple sclerosis in Iran?
    Acta Neurol Scand. 2019 Jul 10. doi: 10.1111/ane.13148.
    >> Share

  37. LAAKSO SM, Viitala M, Kuusisto H, Sarasoja T, et al
    Multiple sclerosis in Finland 2018- data from the national register.
    Acta Neurol Scand. 2019 Jul 4. doi: 10.1111/ane.13145.
    >> Share

  38. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Real-life use of oral disease-modifying treatments in Austria.
    Acta Neurol Scand. 2019;140:32-39.
    >> Share

    May 2019
  39. GASCOYNE CR, Simpson S Jr, Chen J, van der Mei I, et al
    Modifiable factors associated with depression and anxiety in multiple sclerosis.
    Acta Neurol Scand. 2019 May 23. doi: 10.1111/ane.13132.
    >> Share

  40. DE FLON P, Laurell K, Sundstrom P, Blennow K, et al
    Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
    Acta Neurol Scand. 2019;139:462-468.
    >> Share

  41. AXELSSON M, Dubuisson N, Novakova L, Malmestrom C, et al
    Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
    Acta Neurol Scand. 2019;139:422-427.
    >> Share

    March 2019
  42. CORTES-MARTINEZ A, Matias-Guiu JA, Pytel V, Montero P, et al
    What is the meaning of PASAT rejection in Multiple Sclerosis?
    Acta Neurol Scand. 2019 Mar 25. doi: 10.1111/ane.13090.
    >> Share

    February 2019
  43. ENGELS K, Schiffmann I, Weierstall R, Rahn AC, et al
    Emotions towards magnetic resonance imaging in people with multiple sclerosis.
    Acta Neurol Scand. 2019 Feb 25. doi: 10.1111/ane.13082.
    >> Share

  44. DE BERNARDO M, Vitiello L, Rosa N
    Optic nerve ultrasound measurement in multiple sclerosis.
    Acta Neurol Scand. 2019 Feb 5. doi: 10.1111/ane.13072.
    >> Share

  45. CANDELIERE MERLICCO A, Gabaldon Torres L, Villaverde Gonzalez R, Fernandez Romero I, et al
    Response to: Comment on "Transorbital ultrasonography for measuring optic nerve atrophy in multiple sclerosis".
    Acta Neurol Scand. 2019 Feb 5. doi: 10.1111/ane.13076.
    >> Share

  46. SANDROFF BM, Baird JF, Silveira SL, Motl RW, et al
    Response heterogeneity in fitness, mobility and cognition with exercise-training in MS.
    Acta Neurol Scand. 2019;139:183-191.
    >> Share

    January 2019
  47. RAHN AC, Kopke S, Stellmann JP, Schiffmann I, et al
    Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review.
    Acta Neurol Scand. 2019;139:18-32.
    >> Share

    November 2018
  48. PIRTTISALO AL, Soilu-Hanninen M, Sipila JOT
    Multiple sclerosis epidemiology in Finland: regional differences and high incidence.
    Acta Neurol Scand. 2018 Nov 27. doi: 10.1111/ane.13057.
    >> Share

  49. DAL-BIANCO A, Wenhoda F, Rommer PS, Weber M, et al
    Do Elevated Autoantibodies in Patients With Multiple Sclerosis Matter ?
    Acta Neurol Scand. 2018 Nov 17. doi: 10.1111/ane.13054.
    >> Share

  50. MELBYE P, Olsson A, Hansen TH, Sondergaard HB, et al
    Short-Chain Fatty Acids and Gut Microbiota in Multiple Sclerosis.
    Acta Neurol Scand. 2018 Nov 14. doi: 10.1111/ane.13045.
    >> Share

  51. STEENHOF M, Nielsen NM, Stenager E, Kyvik K, et al
    Distribution of disease courses in familial versus sporadic multiple sclerosis.
    Acta Neurol Scand. 2018 Nov 9. doi: 10.1111/ane.13044.
    >> Share

    October 2018
  52. HOLMOY T, Rosjo E, Zetterberg H, Blennow K, et al
    Vitamin D supplementation and neurofilament light chain in multiple sclerosis.
    Acta Neurol Scand. 2018 Oct 13. doi: 10.1111/ane.13037.
    >> Share

  53. BAYART JL, Muls N, van Pesch V
    Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute?
    Acta Neurol Scand. 2018;138:352-358.
    >> Share

    August 2018
  54. HAGHIGHI S, Forsmark S, Carlsson A, Nilsson MKL, et al
    Open study with (-)-OSU6162 in multiple sclerosis-related fatigue.
    Acta Neurol Scand. 2018 Aug 22. doi: 10.1111/ane.13007.
    >> Share

  55. BAUMGARTNER A, Frings L, Schiller F, Stich O, et al
    Regional neuronal activity in patients with relapsing remitting multiple sclerosis.
    Acta Neurol Scand. 2018 Aug 8. doi: 10.1111/ane.13012.
    >> Share

    July 2018
  56. MURLEY C, Yang F, Gyllensten H, Alexanderson K, et al
    Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 24. doi: 10.1111/ane.13001.
    >> Share

  57. ROMEO MAL, Martinelli V, Dalla Costa G, Colombo B, et al
    Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.
    Acta Neurol Scand. 2018 Jul 22. doi: 10.1111/ane.12999.
    >> Share

  58. GAVRILOV YV, Shkilnyuk GG, Valko PO, Stolyarov ID, et al
    Validation of the Russian version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Jul 9. doi: 10.1111/ane.12993.
    >> Share

  59. CANDELIERE MERLICCO A, Gabaldon Torres L, Villaverde Gonzalez R, Fernandez Romero I, et al
    Transorbital ultrasonography for measuring optic nerve atrophy in multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 2. doi: 10.1111/ane.12976.
    >> Share

    June 2018
  60. DALE GH, Svendsen KB, Gjelstrup MC, Christensen T, et al
    Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region.
    Acta Neurol Scand. 2018;137:582-588.
    >> Share

    May 2018
  61. BERNTSSON SG, Kristoffersson A, Bostrom I, Feresiadou A, et al
    Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
    Acta Neurol Scand. 2018 May 24. doi: 10.1111/ane.12963.
    >> Share

  62. SEBASTIAO E, Motl RW
    Body mass index and cardiorespiratory fitness in persons with multiple sclerosis.
    Acta Neurol Scand. 2018 May 11. doi: 10.1111/ane.12959.
    >> Share

  63. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Eckert S, et al
    Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study.
    Acta Neurol Scand. 2018 May 9. doi: 10.1111/ane.12958.
    >> Share

    March 2018
  64. HEYDARPOUR P, Manouchehrinia A, Beiki O, Mousavi SE, et al
    Smoking and worsening disability in multiple sclerosis: A meta-analysis.
    Acta Neurol Scand. 2018 Mar 15. doi: 10.1111/ane.12916.
    >> Share

  65. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921.
    >> Share

  66. RAHMANZADEH R, Weber MS, Bruck W, Navardi S, et al
    B cells in multiple sclerosis therapy-A comprehensive review.
    Acta Neurol Scand. 2018 Mar 7. doi: 10.1111/ane.12915.
    >> Share

    February 2018
  67. MANI A, Chohedri E, Ravanfar P, Mowla A, et al
    Efficacy of group cognitive rehabilitation therapy in multiple sclerosis.
    Acta Neurol Scand. 2018 Feb 7. doi: 10.1111/ane.12904.
    >> Share

  68. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Real-life clinical use of natalizumab and fingolimod in Austria.
    Acta Neurol Scand. 2018;137:181-187.
    >> Share

  69. NICKEL S, von dem Knesebeck O, Kofahl C
    Self-assessments and determinants of HRQoL in a German MS population.
    Acta Neurol Scand. 2018;137:174-180.
    >> Share

    January 2018
  70. MESCHERIAKOVA JY, Hintzen RQ
    No excess of autoimmune diseases in multiple sclerosis families from the Netherlands.
    Acta Neurol Scand. 2018 Jan 7. doi: 10.1111/ane.12896.
    >> Share

  71. RORSMAN I, Petersen C, Nilsson PC
    Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Acta Neurol Scand. 2018;137:117-124.
    >> Share

    December 2017
  72. OLSSON A, Oturai AB, Sondergaard HB, Sellebjerg F, et al
    Bone microarchitecture and bone mineral density in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 21. doi: 10.1111/ane.12884.
    >> Share

  73. ZECCA C, Antozzi CG, Torri Clerici V, Ferrazzini M, et al
    Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12882.
    >> Share

  74. HEESEN C, Haase R, Melzig S, Poettgen J, et al
    Perceptions on the value of bodily functions in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12881.
    >> Share

    November 2017
  75. ZETTERBERG H
    Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:15-17.
    >> Share

  76. LYCKE J
    Trials of antivirals in the treatment of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:45-48.
    >> Share

  77. CELIUS EG
    Infections in patients with multiple sclerosis: Implications for disease-modifying therapy.
    Acta Neurol Scand. 2017;136 Suppl 201:34-36.
    >> Share

  78. WEKERLE H
    Nature, nurture, and microbes: The development of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:22-25.
    >> Share

  79. FREDERIKSEN JL, Topsoe Mailand M
    Vaccines and multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:49-51.
    >> Share

  80. WENDEL-HAGA M, Celius EG
    Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
    Acta Neurol Scand. 2017;136 Suppl 201:26-30.
    >> Share

    August 2017
  81. WALLIN MT, Culpepper WJ, Maloni H, Kurtzke JF, et al
    The Gulf War era multiple sclerosis cohort: 3. Early clinical features.
    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12810.
    >> Share

    July 2017
  82. ANDERSEN O, Hildeman A, Longfils M, Tedeholm H, et al
    Diffusion tensor imaging in multiple sclerosis at different final outcomes.
    Acta Neurol Scand. 2017 Jul 25. doi: 10.1111/ane.12797.
    >> Share

  83. CAMBRON M, Hadhoum N, Duhin E, Lacour A, et al
    JCV serology in time: 3 years of follow-up.
    Acta Neurol Scand. 2017;136:54-58.
    >> Share

    May 2017
  84. MENTIS AA, Dardiotis E, Grigoriadis N, Petinaki E, et al
    Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation.
    Acta Neurol Scand. 2017 May 23. doi: 10.1111/ane.12775.
    >> Share

    April 2017
  85. MARTINELLI V, Dalla Costa G, Messina MJ, Di Maggio G, et al
    Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.
    Acta Neurol Scand. 2017 Apr 9. doi: 10.1111/ane.12761.
    >> Share

    March 2017
  86. ELKJAER ML, Molnar T, Illes Z
    Teriflunomide for multiple sclerosis in real-world setting.
    Acta Neurol Scand. 2017 Mar 20. doi: 10.1111/ane.12755.
    >> Share

  87. SCHNEIDER R, Bellenberg B, Kleiter I, Gold R, et al
    Cervical cord and ventricle affection in neuromyelitis optica.
    Acta Neurol Scand. 2017;135:324-331.
    >> Share

    February 2017
  88. ENSARI I, Pilutti LA, Motl RW
    Depressive symptomology in multiple sclerosis: Disability, cardiorespiratory fitness and heart rate variability.
    Acta Neurol Scand. 2017 Feb 26. doi: 10.1111/ane.12748.
    >> Share

    January 2017
  89. LUNDELL H, Svolgaard O, Dogonowski AM, Romme Christensen J, et al
    Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
    Acta Neurol Scand. 2017 Jan 10. doi: 10.1111/ane.12729.
    >> Share

  90. VOLDSGAARD A, Koch-Henriksen N, Magyari M, Sellebjerg F, et al
    Early safety and efficacy of fingolimod treatment in Denmark.
    Acta Neurol Scand. 2017;135:129-133.
    >> Share

    December 2016
  91. KARAMYAN A, Brandtner H, Grinzinger S, Chroust V, et al
    Causes of death in critically ill multiple sclerosis patients.
    Acta Neurol Scand. 2016 Dec 23. doi: 10.1111/ane.12724.
    >> Share

  92. TANASESCU R, Midgley A, Robins RA, Constantinescu CS, et al
    Decreased interferon-beta induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Acta Neurol Scand. 2016 Dec 5. doi: 10.1111/ane.12715.
    >> Share

  93. D'HOOGHE MB, Haentjens P, Van Remoortel A, De Keyser J, et al
    Self-reported levels of education and disability progression in multiple sclerosis.
    Acta Neurol Scand. 2016;134:414-419.
    >> Share

    November 2016
  94. PEARSON JF, Alla S, Clarke G, Mason DF, et al
    Multiple Sclerosis impact on employment and income in New Zealand.
    Acta Neurol Scand. 2016 Nov 28. doi: 10.1111/ane.12714.
    >> Share

  95. SOELBERG SORENSEN P
    Safety concerns and risk management of multiple sclerosis therapies.
    Acta Neurol Scand. 2016 Nov 27. doi: 10.1111/ane.12712.
    >> Share

    October 2016
  96. ZETTL UK, Schreiber H, Bauer-Steinhusen U, Glaser T, et al
    Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 30. doi: 10.1111/ane.12705.
    >> Share

  97. GOUVEIA A, Dias SP, Santos T, Rocha H, et al
    Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 24. doi: 10.1111/ane.12702.
    >> Share

    September 2016
  98. PUZ P, Lasek-Bal A, Radecka P
    Transcranial sonography of subcortical structures in patients with multiple sclerosis.
    Acta Neurol Scand. 2016 Sep 18. doi: 10.1111/ane.12689.
    >> Share

  99. ROMMER PS, Suhnel A, Konig N, Zettl UK, et al
    Coping with multiple sclerosis-the role of social support.
    Acta Neurol Scand. 2016 Sep 12. doi: 10.1111/ane.12673.
    >> Share

  100. MUCKSCHEL M, Beste C, Ziemssen T
    Immunomodulatory treatments and cognition in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:55-9.
    >> Share

  101. BERGER T
    Immunological processes related to cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:34-8.
    >> Share

  102. PAUL F
    Pathology and MRI: exploring cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:24-33.
    >> Share

  103. PORTACCIO E
    Differential diagnosis, discerning depression from cognition.
    Acta Neurol Scand. 2016;134 Suppl 200:14-8.
    >> Share

  104. HAMALAINEN P, Rosti-Otajarvi E
    Cognitive impairment in MS: rehabilitation approaches.
    Acta Neurol Scand. 2016;134 Suppl 200:8-13.
    >> Share

  105. VAN ETTINGER-VEENSTRA H
    Cumulative evidence for MS as a neural network disconnection syndrome consistent with cognitive impairment mechanisms and the confounding role of fatigue and depression-outlook from the Fourth Nordic MS symposium.
    Acta Neurol Scand. 2016;134 Suppl 200:4-7.
    >> Share

    May 2016
  106. KOLASA M, Hagman S, Verkkoniemi-Ahola A, Airas L, et al
    Anti-JC virus seroprevalence in a Finnish MS cohort.
    Acta Neurol Scand. 2016;133:391-7.
    >> Share

    April 2016
  107. HOLMOY T, Esbensen QY, Torkildsen O, Wergeland S, et al
    WT1 and interferon-beta-vitamin D association in MS: a longitudinal study.
    Acta Neurol Scand. 2016;133:309-12.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016